3Wellington K, Goa KL. Zoledronic acid - a review of its use in the management of bone metastases and hypercalcaemia of malignancy [J]. Drugs, 2003, 63 (4): 417.
4Berenson JR, Vescio R, Henick K, et al. A phaseⅠ, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonte, in cancer patients with metastatic bone disease [J]. Cancer, 2001, 91 (1): 144.
5Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. Zoledronic acid prostate cancer study group [J]. J Natl Cancer Inst, 2002, 94 (19): 1458.
6Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials [J]. J Clin Oncol, 2001, 19 (2): 558.
7Body JJ, Lortholary A, Romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients [J]. J Bone Miner Res, 1999, 14 (9): 1557.
8Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density [J]. N Engl J Med, 2002, 346 (9): 653.
9Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blin
10Weinfurt KP, Castel LD, Li Y, et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions [J]. Med Care, 2004, 42 (2): 164.
二级参考文献21
1[1]Coleman R E. Skeletal complications of malignancy. Cancer, 1997(suppl 8), 8 0:1588
2[2]Coleman R E. Should bisphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol, 2001(Supple 11),28(4):35
3[3]Allan Lipton. Bisphosphonates and breast carcinoma. Cancer, 1997(su ppl 8), 80:1668
4[4]Chlebowski R T. Factors influencing the role of bisphosphonates in breast cancer management. Semin Oncol, 2001(Supple 11),28(4):42-48
5[5]Hillner B E, Ingle J N, Berenson J R,et al. American Society o f Clinical Onco logy Guideline on the role of bisphosphonates in breast cancer. J Clin Oncol, 2000, 18:1378
6[6]Coleman R E. Uses and abuses of bisphosphonates. Ann Oncol, 2000, 1 1:179
7[7]Mundy G R. Mechanisms of bone metastasis. Cancer, 1997(suppl 8),80 :1546
8[8]Paterson A H G. The potential role of bisphosphonates as adjuvant t herapy in the prevention of bone metastases. Cancer, 2000, 88:3038
9[9]Van der Pluijm G, Lowik C, Papapoulos S. Tumor progression and angi ogenesis in bone metastasis from breast cancer: New approaches to an old problem. Cancer Treat Rev, 2000, 26:11
10[10]Rogers M J, Watts D J, Russell R G G. Overview of bisphosphonates. Cancer, 1997(suppl 8),80:1652
